ChBME – Joint | Chemical and Biomedical Engineering
Biography
Diana Gil Pagés’ research investigates how antigen recognition by T cell receptors (TCRs) turns on cell adaptive immune function. Specifically, she is focused on the TCR-associated CD3 multiprotein complex and is the principal discoverer of the CD3 conformational change (CD3Dc), which is at the foundation of her ongoing research. Gil Pagés is studying the various levels of control exercised over CD3Dc, including structural, biochemical, developmental and physiological aspects. Her work is grounded in technical innovation and data reproducibility with an emphasis in biochemistry and primary immune cell function. She is building on the current understanding of CD3Dc to translate knowledge into in vivo therapies for metastatic cancers with focus areas on fragment antigen-binding (Fab) fragments.
Education
PhD from Universidad Autonoma de Madrid
Fellowship from University Hospital, Basel, Switzerland
Technical Focus
Central and peripheral tolerance
Development of novel cancer immunotherapies